Stephens raised the firm’s price target on PacBio (PACB) to $2 from $1.80 and keeps an Overweight rating on the shares. While noting that the company reported Q3 results that missed expectations, the firm thinks expanding Revio utilization has potential to support upside to its consumable estimates and contends that NIH clarity could drive stronger instruments than it models.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PACB:
- Pacific Biosciences’ Earnings Call: Mixed Results and Strategic Outlook
- Pacific Biosciences: Overcoming Short-Term Challenges with Strategic Innovations and Long-Term Growth Prospects
- Pacific Biosciences: Strong Consumable Growth and New Product Launches Drive Buy Rating
- Pacific Biosciences Reports Q3 2025 Financial Results
- PacBio reports Q3 EPS (13c), consensus (14c)